
Please try another search
TNF Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog of derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. The company has a strategic alliance with DADA2 Foundation for research into the rare inflammatory disease DADA2 (Deficiency of Adenosine Deaminase 2). TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in New York, New York.
Name | Age | Since | Title |
---|---|---|---|
Craig Eagle | 58 | 2021 | Independent Director |
Stephen A. Friscia | 54 | 2024 | Independent Director |
Jude C. Uzonwanne | 49 | 2021 | Independent Director |
Joshua N. Silverman | 55 | 2018 | Independent Chairman of the Board |
Christopher C. Schrieber | 60 | 2017 | Director |
Billy Joe White | 64 | 2017 | Independent Director |
Mitchell Glass | 73 | 2024 | President, Chief Medical Officer & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review